LAB vs AZTA vs PACB vs CDNA vs ILMN

For growth investors, CareDx, Inc (CDNA) is the stronger pick with 13.

8% revenue growth year-over-year, versus -51. 1% for Standard BioTools Inc. (LAB). Illumina, Inc. (ILMN) offers the better valuation at 25. 5x trailing P/E (26. 8x forward), making it the more compelling value choice. Analysts rate Standard BioTools Inc. (LAB) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, CareDx, Inc is actually cheaper at 22.

8x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Illumina, Inc.

(ILMN) delivered a total return of -62. 8%, compared to -93. 4% for Pacific Biosciences of California, Inc. (PACB). Over 10 years, the gap is even starker: CDNA returned +385. 1% versus LAB's -89. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Illumina, Inc.

(ILMN) is the lower-risk stock at 1. 23β versus Pacific Biosciences of California, Inc. 's 2. 43β — meaning PACB is approximately 97% more volatile than ILMN relative to the S&P 500. On balance sheet safety, Azenta, Inc. (AZTA) carries a lower debt/equity ratio of 6% versus 142% for Pacific Biosciences of California, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), CareDx, Inc (CDNA) is pulling ahead at 13.

8% versus -51. 1% for Standard BioTools Inc. (LAB). On earnings-per-share growth, the picture is similar: Illumina, Inc. grew EPS 170. 9% year-over-year, compared to -143. 0% for CareDx, Inc. Over a 3-year CAGR, PACB leads at 7. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Illumina, Inc.

(ILMN) is the more profitable company, earning 19. 6% net margin versus -341. 5% for Pacific Biosciences of California, Inc. — meaning it keeps 19. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ILMN leads at 19. 9% versus -348. 5% for PACB. At the gross margin level — before operating expenses — CDNA leads at 67. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, CareDx, Inc (CDNA) trades at 22.

8x forward P/E versus 26. 8x for Illumina, Inc. — 3. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for LAB: 225. 0% to $3. 25.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, CareDx, Inc (CDNA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+385.

1% 10Y return). Standard BioTools Inc. (LAB) carries a higher beta of 2. 01 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CDNA: +385. 1%, LAB: -89. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.